Emergent BioSolutions, Inc. (NYSE:EBS)

CAPS Rating: 4 out of 5

A biopharmaceutical company focused on the development, manufacture and commercialization of immunobiotics. The Company operates in two business segments: biodefense and commercial.

Recs

0
Player Avatar Clint35 (60.96) Submitted: 4/5/2010 9:19:19 PM : Outperform Start Price: $16.67 EBS Score: -29.37

A cheap biotech with 5 stars.

Featured Broker Partners


Advertisement